Pluvicto Improves Survival Without Progression in Certain Pa

Patients with metastatic castration-resistant prostate cancer who were never treated with a taxane derived a progression-free survival benefit from treatment with Pluvicto.

Related Keywords

Mayo Clinic In Rochester , Minnesota , United States , Spain , Madrid , A Oliver Sartor , Zytiga Xtandi , European Society For Medical Oncology Annual Congress , Medical Oncology Annual Congress , Mayo Clinic , Prostate Cancer , Jesmo , Esmo 2023 ,